End point Muraglitazar 5 mg plus metformin (n=569)

Slides:

Advertisements

Similar presentations

Relationship of LDL-C & LDL-P. Lipoprotein Particles LipoScience 2007 NON-POLAR LIPID CORE Cholesterol Ester Triglyceride POLAR SURFACE COAT Phospholipid.

Advertisements

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients with or without Comorbidities A Randomised Double-Blind.

Clinical Trial Results. org The ERASE Trial: Effect of rHDL on Atherosclerosis-Safety and Efficacy Presented at American College of Cardiology Annual Scientific.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

Rimonabant in Obesity Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres RIO LIPIDS Trial.

© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.

PPAR  activation & lipid metabolism. Diabetic dyslipidaemia Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients Niskanen.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

Diabetes and High Blood Pressure Are Like Twins. Ignoring Your High Blood Pressure.

Sglt-2 insulin Matthews D, Fulcher G, Perkovic V, et al. Ef  cacy and safety of canagliflozin,an inhibitor of sodium glucose co-transporter 2, added.

1 A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia Diabetes Care 28:1547–1554,

Parameters BD PP CP TC (mg. dl-l) ± * ± 5.8

The American College of Cardiology Presented by Dr. Nikolaus Marx

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels Michael H. Davidson, MD Journal of Clinical.

RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR

Adding rosiglitazone to metformin in patients with type 2 diabetes: Effect on diabetes control and metabolic parameters Hussein Raef, Abdulraof Al-Mahfouz,

Copyright © 2002 American Medical Association. All rights reserved.

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.

The American Heart Association Presented by Dr. Steven E. Nissen

Potential effects of 10kg wt loss in Type 2 diabetes

The Latest Lipid Guidelines:

End point Rimonabant 20 mg (n=339) Placebo (n=348) p Weight (kg) -5.3

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Time frame : Baseline to post intervention

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

The ASSERT Study.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

The PPAR Journey: What Can We Expect in the Future?

The PPAR Journey: What Can We Expect in the Future?

Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

Baseline characteristics of HPS participants by prior diabetes

Placebo group 5-mg rimonabant group p 20-mg rimonabant group

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the.

Description of studies for pooled analyses

VALUE: New-onset diabetes in an amlodipine-based vs valsartan-based therapy in high-risk hypertensives Diagnostic criteria Valsartan n (%) Amlodipine n.

Subject Characteristics

Hajer GR et al. Atherosclerosis 2009;202:216-24

Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.

OmniHeart Feeding Study

NGM282 in NASH: 3 mg vs 6 mg QD (phase 2)

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.

The American College of Cardiology Presented by Dr. Nikolaus Marx

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Volume 67, Issue 4, Pages (April 2005)

Obese gestational diabetes mellitus (GDM) women demonstrate significant dyslipidemia at 26 weeks of gestation compared to obese women without diabetes.

VK2809 in NAFLD: a phase 2 study

PROSPER: trial design

TNT diabetes analysis: Baseline and final LDL cholesterol levels

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

Change in markers of glycometabolism and cardiovascular risk profile.

Adjusted relative risk Adjusted odds ratio

Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Correlation between progranulin (dependent variable) and CKD stage adjusted for age and sex, as well as DBP, WHR, triglycerides, HDL cholesterol, LDL cholesterol,

Effects of pterosin A on serum levels of lipid, blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), and alanine aminotransferase (ALT)

Fig. 2. Changes in glycosylated hemoglobin (HbA1c) levels

Effect of empagliflozin on efficacy parameters at week 18.

Study design (A) and patient disposition (B).

FIGURE 1 Results for primary meta-analysis of controlled trials for the effects of walnut-enriched compared with ... FIGURE 1 Results for primary meta-analysis.

ROC curves for LDL cholesterol, apoB, non-HDL cholesterol, and the total cholesterol–to–HDL cholesterol ratio deciles. ROC curves for LDL cholesterol,

© The Author(s) Published by Science and Education Publishing.

Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Absolute change in HbA1c levels in the muraglitazar and pioglitazone study arms at week 24 End point Muraglitazar 5 mg plus metformin (n=569) Pioglitazone 30 mg plus metformin (n=550) HbA1c difference between study arms p Change in HbA1c levels (%) -1.14 -0.85 0.29 <0.0001 Kendall D. American Diabetes Association 2005 Scientific Sessions; June 10-14, 2005; San Diego, CA.

Relative change in lipid parameters from baseline in the muraglitazar and pioglitazone study arms at week 12 End point Muraglitazar 5 mg plus metformin (n=569) Pioglitazone 30 mg plus metformin (n=550) p Change in triglyceride levels (%) -28.4 -13.4 <0.0001 Change in HDL cholesterol levels (%) 19.2 13.6 Change in apolipoprotein B levels (%) -11.8 -6.0 Change in non-HDL cholesterol levels (%) -5.9 -1.2 Kendall D. American Diabetes Association 2005 Scientific Sessions; June 10-14, 2005; San Diego, CA.